The first oral glucagon-like peptide-1 (GLP-1) drug has launched nationwide, marking a major expansion of access to the popular treatments credited with reshaping obesity care in the US.

The first oral glucagon-like peptide-1 (GLP-1) drug has launched nationwide, marking a major expansion of access to the popular treatments credited with reshaping obesity care in the US.

Last month, Novo Nordisk NVO announced the FDA approval of the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction in the long term, and to reduce the risk of major adverse cardiovascular (CV) events.